Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome

The Korean Society of Haematology AML/MDS Working Party

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)e151-e155
JournalBritish Journal of Haematology
Volume186
Issue number5
DOIs
Publication statusPublished - 2019

Keywords

  • Hypomethylating agent
  • MDS
  • lenalidomide

ASJC Scopus subject areas

  • Hematology

Cite this